VRTX
HEALTHCAREVertex Pharmaceuticals Inc
$427.65+3.29 (+0.78%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving VRTX Today?
No stock-specific AI insight has been generated for VRTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$362.50$507.92
$427.65
Fundamentals
Market Cap$108.5B
P/E Ratio25.4
EPS$16.85
Dividend Yield—
Dividend / Share—
ROE0.2%
Profit Margin0.4%
Debt / Equity—
Trading
Volume1.2M
Avg Volume (10D)—
Shares Outstanding253.8M
VRTX News
30 articles- Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety ProfileMarketbeat·May 9, 2026
- VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 EarningsYahoo Finance·May 8, 2026
- Gene Therapy Briefs: Regeneron Wins FDA Approval for First Neurosensory Gene TherapyGenetic Engineering and Biotechnology News·May 8, 2026
- Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to KnowYahoo Finance·May 8, 2026
- Is It Time To Reassess Vertex (VRTX) After Recent Share Price Weakness?Simply Wall Street·May 8, 2026
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Just Released Its First-Quarter Results And Analysts Are Updating Their EstimatesYahoo Finance·May 7, 2026
- Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in GermanyYahoo Finance·May 6, 2026
- Is It Too Late To Consider Vertex Pharmaceuticals (VRTX) After Recent Share Price WeaknessYahoo Finance·May 6, 2026
- NKF Honors Vertex with 2026 Kidney Biotech Innovation AwardYahoo Finance·May 6, 2026
- Is This Millionaire-Maker Biotech Stock a Buy Right Now?The Motley Fool·May 6, 2026
- Vertex Dips On Mixed First-Quarter Report; But There's A Silver LiningYahoo Finance·May 5, 2026
- Vertex Pharmaceuticals Confident in Emerging Renal Franchise, Oppenheimer SaysYahoo Finance·May 5, 2026
- VRTX's Q1 Earnings Beat Estimates, New Products Aid Sales GrowthYahoo Finance·May 5, 2026
- Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?Yahoo Finance·May 5, 2026
- US Equity Futures Gain Pre-Bell as Traders Keep Eye on Potential Re-Escalation of Middle East HostilitiesYahoo Finance·May 5, 2026
- CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss EstimatesYahoo Finance·May 5, 2026
- US Equity Futures Higher Pre-Bell as Traders Keep Eye on Potential Re-Escalation of Middle East HostilitiesYahoo Finance·May 5, 2026
- Vertex earnings get muted investor responseBiopharmadive·May 5, 2026
- Vertex Pharmaceuticals Incorporated Q1 2026 Earnings Call SummaryMoby·May 5, 2026
- Vertex Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 5, 2026
- Vertex (VRTX) Q1 2026 Earnings Call TranscriptMotley Fool·May 4, 2026
- Vertex (VRTX) Reports Q1 Earnings: What Key Metrics Have to SayYahoo Finance·May 4, 2026
- Got $1,000? Which of These Beaten-Down Healthcare Stocks Is Worth Buying?The Motley Fool·May 2, 2026
- IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsightGlobeNewswire Inc.·Apr 29, 2026
- CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy?The Motley Fool·Apr 21, 2026
- Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated CellsBenzinga·Apr 10, 2026
- Global DNA Read, Write and Edit Market to Surge to $67.7 Billion by 2030, Driven by CRISPR Advances, Genomic Diagnostics and Expanding Clinical ApplicationsGlobeNewswire Inc.·Apr 7, 2026
- Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsightGlobeNewswire Inc.·Apr 6, 2026
- Where Will Vertex Pharmaceuticals Be in 1 Year?The Motley Fool·Mar 25, 2026
- Anti-Aging Protein Research Takes a Step Forward with Cell CloningBenzinga·Mar 24, 2026
All 30 articles loaded
Price Data
Open$422.67
Previous Close$424.36
Day High$431.06
Day Low$422.67
52 Week High$507.92
52 Week Low$362.50
52-Week Range
$362.50$507.92
$427.65
Fundamentals
Market Cap$108.5B
P/E Ratio25.4
EPS$16.85
Dividend Yield—
Dividend / Share—
ROE0.2%
Profit Margin0.4%
Debt / Equity—
Trading
Volume1.2M
Avg Volume (10D)—
Shares Outstanding253.8M
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—